Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

1 month ago Solid tumor

Published in Cell Journal | Breakthrough in dMMR Metastatic Colorectal Cancer Treatment: Chinese Research Garners International Recognition

Colorectal Cancer

#ColorectalCancer #PD1Antibody #dMMR #cell #cellpress #Med #PD-1 #CellJournal

A Chinese medical team has made a significant breakthrough in the treatment of dMMR (deficient mismatch repair) metastatic colorectal cancer. Recently, their latest research findings were published in the Med journal, a subsidiary of Cell, offering new treatment hope for patients with advanced colorectal cancer.

The study revealed that the combination of PD-1 antibody immunotherapy with COX inhibitors, drugs commonly used for anti-inflammatory treatment, significantly improved treatment effectiveness. This innovative strategy could substantially increase survival chances for patients with advanced colorectal cancer.

Colorectal cancer is the second most common cancer in China, and its incidence is on the rise. While PD-1 antibody immunotherapy has brought hope to some patients, its success rate is only 45%. Approximately 30% of dMMR metastatic colorectal cancer patients are resistant to PD-1 treatment. Therefore, the Chinese team explored combining PD-1 immunotherapy with COX inhibitors (such as celecoxib and aspirin) to overcome this resistance.

The team’s Phase 2 clinical trial yielded remarkable results. Among the 30 patients who received the combination therapy, the overall response rate was 73.3%, a 30% improvement over PD-1 monotherapy. After more than four years of follow-up, 65% of patients achieved progression-free survival, and 90% were still alive. Four patients reached complete remission, while 11 others underwent surgery, with 10 showing complete pathological remission.

In addition to the notable clinical outcomes, genomic and immunological analysis revealed that high expression of the TAPBP protein was associated with better treatment results. This discovery opens new avenues for the development of biomarkers to predict treatment response and for personalized treatment plans in the future.

Following the publication of the study, it attracted significant attention from the international medical community. Experts from Memorial Sloan Kettering Cancer Center in the U.S. wrote a commentary in the Med journal, highly praising the innovative therapy. They noted that the combination of COX inhibitors with PD-1 treatment not only increased the complete remission rate but also reduced immune suppression signals in the tumor microenvironment, enhancing the effectiveness of PD-1 therapy, with manageable side effects.

This research offers new hope for dMMR metastatic colorectal cancer patients worldwide, and further large-scale clinical trials are expected to confirm its efficacy. The combination of COX inhibitors with PD-1 immunotherapy could become a safe and effective treatment option for dMMR metastatic colorectal cancer patients, providing hope for long-term survival.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070

（Https://wa.me/+8613717959070）
Email: doctor.huang@globecancer.com

#CancerResearch #MedicalInnovation #GlobalHealth #Immunotherapy #Colorectal #COXInhibitors

3 months ago Solid tumor

Hope to Eradicate Lung Cancer, Colorectal Cancer, and Various Solid Tumors! China’s First Self-Replicating mRNA Vaccine JCXH-211 Successfully Launched~

mRNA Vaccine

Tumor immunotherapy, as an emerging method for diagnosing and treating tumors, has garnered widespread attention since its inception. Prior to the advent of tumor immunotherapy, the clinical treatment of solid tumors relied solely on traditional surgical removal, radiotherapy, and chemotherapy. Although these methods were effective, they came with significant drawbacks such as drug side effects and the risk of recurrence.

Since the 1990s, mRNA vaccines have been considered therapeutic vaccines. During the COVID-19 pandemic in 2020, mRNA vaccines were used in clinical treatments, saving countless lives. Today, as the advantages of mRNA vaccines are gradually being discovered, they are now applied in multiple fields.

The advent of China’s first self-replicating mRNA vaccine JCXH-211 undoubtedly marks a new breakthrough in the clinical diagnosis and treatment of various solid tumors in China.

What is the mRNA Vaccine JCXH-211?

JCXH-211 is the world’s first self-replicating RNA drug encoding human interleukin-12 (IL-12) to enter clinical trials. This srRNA vaccine delivers mRNA encoding IL-12 into the cytoplasm, continuously expressing IL-12 to enhance the body’s immune response against tumor cells.

In preclinical studies involving various mouse and PDX disease models, JCXH-211 has shown the ability to effectively kill tumor cells, eliminate distant tumors, and prevent tumor recurrence. Comprehensive GLP toxicology studies have also demonstrated good safety.

JCXH-211 has a broad range of indications and is expected to effectively treat multiple solid tumors. The anticipated prospects are as follows:

1. Lung Cancer:

As one of the leading causes of cancer death worldwide, lung cancer is often diagnosed at a late stage due to difficulties in early detection. JCXH-211, through continuous expression of IL-12 and activation of immune cells, is expected to effectively control the growth and spread of lung cancer cells.

2. Colorectal Cancer:

Current clinical treatments for colorectal cancer primarily involve surgery and radiotherapy/chemotherapy, which can remove visible tumors but have a high recurrence rate. Periodic administration of JCXH-211 may significantly reduce recurrence and improve patient survival.

3. Soft Tissue/Chondrosarcoma:

These tumors are highly invasive and cover a wide range of areas, often affecting surrounding soft tissues and progressing rapidly. Current treatments are limited to surgery and radiotherapy/chemotherapy, which, although somewhat effective, are not thorough, leading to high recurrence rates. JCXH-211 could become a new treatment method, enhancing the body’s immune response to combat these stubborn cancer cells.

4. Skin Cancer:

Clinical treatments for skin cancer mainly include surgery and radiotherapy. While most skin cancers have a good prognosis, the effects on intractable melanoma are poor. The expression of IL-12 can activate specific T cells, greatly aiding in the elimination of melanoma cells.

High-Efficiency Activation and Safety of the mRNA Vaccine JCXH-211!

mRNA vaccines not only encode antigens to induce specific immune responses against tumors but also possess inherent immunostimulatory properties. This dual mechanism allows JCXH-211 to activate the immune system more efficiently, enhancing the overall anti-tumor effect.

Moreover, the safety of mRNA vaccines is well-recognized. Since DNA is the genetic material of most species, including humans and viruses, and is transcribed into mRNA before being translated into proteins to perform functions in the body, injecting mRNA into the human body does not enter the cell nucleus, thereby eliminating the risk of genomic insertion mutations. Additionally, mRNA can be naturally degraded and excreted from the body, preventing accumulation. Thus, JCXH-211 presents lower potential risks and is safer.

Currently, clinical trials are progressing steadily. With the rapid advancement of tumor immunotherapy, JCXH-211 is expected to become a standard treatment for various solid tumors, offering hope to many cancer patients.

To assess whether the condition is suitable for cancer vaccine or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

6 months ago CAR-T

🔬✨ Overall Response Rate 50%! Chinese Research Entity’s Solid Tumor CAR-T Hits Colorectal Cancer

Colorectal Cancer

#Solidtumor

In the journey to conquer cancer, a significant breakthrough is stirring! Shanghai Sundise Biotech has successfully developed the first candidate product GCC19CART, based on its independently developed CoupledCAR® platform technology. This innovative autologous #CART therapy product is specifically designed to target solid tumors of recurrent/refractory metastatic colorectal cancer (R/R mCRC). Let’s delve into this milestone achievement together!

#GCC19CART

On April 19, 2022, Shanghai Sundise Biotech announced that its solid tumor CAR-T product GCC19CART had been granted Fast Track designation by the U.S. Food and Drug Administration (#FDA). This news implies that the development of GCC19CART will be accelerated, bringing hope and new treatment options to more colorectal cancer patients.

#NCCN

So, what is recurrent/refractory colorectal cancer? According to the definition by the National Comprehensive Cancer Network (NCCN), it refers to patients who have undergone multiple rounds of conventional treatment without success or have developed metastases, facing extremely limited treatment options. Current statistics show that the survival rate and objective response rate of such patients are extremely low, urgently requiring more effective treatment methods.

#colorectalcancer

GCC19CART has demonstrated significant clinical activity by targeting and eliminating cancer cells expressing the colorectal cancer tumor marker GCC. According to publicly available data, GCC is widely expressed in colorectal cancer and is highly expressed in metastatic colorectal cancer cells, making it an ideal target for treatment. Preliminary clinical trial results indicate that GCC19CART exhibits significant objective response rates and acceptable safety profiles in refractory metastatic colorectal cancer, bringing new hope to patients.

#ORR 50%

A multicenter Phase I dose-escalation clinical trial conducted in China showed that the objective response rate in the medium-dose group (2×106 CAR-T/kg) reached an encouraging 50%. This suggests that GCC19CART may become an important choice for treating recurrent/refractory colorectal cancer, bringing longer survival and better quality of life to patients.

#Hope

Colorectal cancer is a disease that seriously threatens human health, and the successful development and clinical trial results of GCC19CART bring us new hope. Let’s look forward together to the early clinical application of this innovative treatment method, bringing light to more patients in need of help!

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: 137 1795 9070
Email: doctor.huang@globecancer.com

💪💊 #ColorectalCancer #CARTtherapy #MedicalInnovation

6 months ago CAR-T

Introducing the Momentum of the Next-Generation “Pan-Cancer” Targeted Therapy ICP-723 of China

Pan-Cancer

ICP-723

On April 11, 2022, InnoCare Pharma unveiled the preclinical data of ICP-723. The research results demonstrate that ICP-723 effectively inhibits the kinase activity of TRKA, TRKB, and TRKC (IC50 value less than 1 nM). Not only does ICP-723 exhibit potent in vitro efficacy in TRK-driven tumors, but it also overcomes resistance mutations commonly seen after treatment with first-generation TRK inhibitors, such as TRKA G595R and TRKC G623R/E.

TGI 89.5%

Further in vivo efficacy studies have confirmed the robust anti-tumor effect of ICP-723 in animal models. At a dosage of 1 mg/kg, ICP-723 achieves a tumor growth inhibition rate (TGI) of 89.5% in the KM12 tumor model. With high oral bioavailability, ICP-723 demonstrates overall favorable pharmacokinetic parameters.

Next-Generation NTRK Inhibitor

ICP-723, a Chinese developed next-generation NTRK inhibitor, holds promise in treating advanced or metastatic solid tumors harboring NTRK fusion genes, including breast cancer, colorectal cancer, lung cancer, thyroid cancer, and patients resistant to first-generation NTRK inhibitors like larotrectinib and entrectinib.

On August 31, 2021, InnoCare Pharma announced the Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to initiate Phase I clinical trials of its second-generation pan-TRK inhibitor ICP-723 in the United States.

In the major financial performance report released by InnoCare Pharma in 2022, the efficacy of ICP-723 was also disclosed.

Objective Response Rate (ORR)

As of February 11, 2022, in the Phase I dose-escalation trial, 17 patients received treatment with ICP-723 at doses ranging from 1 to 8 mg once daily. The safety profile was favorable, with no dose-limiting toxicities (DLT) observed. Among the 17 patients, 5 were confirmed positive for NTRK gene fusion, with an objective response rate (ORR) of 80%, including partial responses in 4 cases, and a disease control rate (DCR) of 100%. In the 4 mg and above dose group, the objective response rate was 100%.

As a novel small molecule second-generation pan-TRK inhibitor, ICP-723 exhibits potent activity and high selectivity, offering the potential to overcome resistance to first-generation TRK inhibitors and better serve patients.

(Note: This clinical trial is still recruiting participants. Patients who have undergone genetic testing can review their reports. Once NTRK1/2/3 fusion is detected, they can immediately contact us Advanced Medicine in China )

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#ICP723 #InnoCarePharma #NTRKInhibitor #CancerTreatment #ClinicalTrials #PrecisionMedicine #HealthcareInnovation #breastcancer #colorectalcancer, #lungcancer, #thyroidcancer

7 months ago CAR-T

🎉💉 Exciting Breakthrough Alert! Chinese Medical Team Unveils Game-Changing mRNA Cancer Vaccine 🎉💉

Advanced Science

Say hello to the future of cancer treatment! A groundbreaking mRNA cancer vaccine jointly developed by Chinese scientists has hit the spotlight, promising to elevate tumor suppression rates and extend survival periods.

🔬 What’s the Buzz? 🔬
Published in the prestigious journal “Advanced Science”, the research titled “All-Trans-Retinoic Acid-Adjuvanted mRNA Vaccine Induces Mucosal Anti-Tumor Immune Responses for Treating Colorectal Cancer” reveals a novel mRNA cancer vaccine. This vaccine, packaged with lipid nanoparticles (LNPs), delivers All-Trans-Retinoic Acid (ATRA) and mRNA, effectively stimulating mucosal immune responses in the intestines. Compared to conventional mRNA-LNP vaccines, this innovative approach significantly boosts tumor suppression and prolongs survival rates.

🩺 Why It Matters 🩺
Colorectal cancer ranks third in cancer incidence and second in mortality globally. Conventional treatments such as surgery, chemotherapy, and radiation often come with high recurrence rates. Enter cancer immunotherapy—the beacon of hope in the fight against colorectal cancer. Cancer vaccines, a vital component of immunotherapy, harness the body’s immune system to target and destroy cancer cells. With the recent success of mRNA vaccines for COVID-19, mRNA cancer vaccines have garnered immense attention for their potential to revolutionize cancer treatment.

🚀 The Breakthrough 🚀
The key lies in ATRA-LNP’s ability to induce cytotoxic T cells in the intestines, offering a promising therapeutic approach for colorectal cancer. In animal models, ATRA-LNP treatment led to a remarkable reduction in tumor growth and extended survival rates compared to conventional treatments. These findings underscore the potential of mRNA cancer vaccines, particularly in enhancing the treatment outcomes for colorectal cancer patients.

🌟 The Takeaway 🌟
With its ability to activate anti-tumor immune responses at mucosal surfaces, the novel mRNA cancer vaccine brings hope for improved outcomes in colorectal cancer treatment. ATRA incorporation into LNPs not only enhances mRNA delivery efficiency but also directs activated T cells towards the intestines, amplifying their anti-tumor effects. This study paves the way for a promising future in enhancing the efficacy of mRNA cancer vaccines against colorectal cancer.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
Email: doctor.huang@globecancer.com,
WhatsApp: 137 1795 9070

#CancerResearch #MedicalBreakthrough #ImmunotherapyInAction #ColorectalCancerFighters #mRNA #CancerVaccine #vaccine #colorectal #colorectalcancer #cancerfighters #chinesemedical #cancertreatment #tumor

Menu

Tags Archives: colorectal cancer

Published in Cell Journal | Breakthrough in dMMR Metastatic Colorectal Cancer Treatment: Chinese Research Garners International Recognition